TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED revenue for the last year amounted to 8.22 B CNY, the most of which — 5.84 B CNY — came from its highest performing source at the moment, Chinese Patent Medicine, the year earlier bringing 5.65 B CNY. The greatest contribution to the revenue figure was made by China — last year it brought TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED 8.16 B CNY, and the year before that — 8.20 B CNY.